Nephrotoxicity of antiretroviral agents: Is the list getting longer?

Journal of Infectious Diseases

Volumn 207, Issue 9, 2013, Pages 1349-1351

  Fine, Derek M ^a   Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; atazanavir; HIV; kidney; lopinavir; nephrotoxicity; renal; tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN L1; ATAZANAVIR PLUS RITONAVIR; CREATININE; CYSTATIN C; EFAVIRENZ; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; PHOSPHATE; TENOFOVIR; UNCLASSIFIED DRUG;

ALLELE; CELL DAMAGE; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; GENETIC RISK; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; KIDNEY TUBULE EXCRETION; LONG TERM EXPOSURE; MODIFICATION OF DIET IN RENAL DISEASE; NEPHROLITHIASIS; NEPHROTOXICITY; NOTE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL SYSTEM PARAMETERS;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RENAL INSUFFICIENCY;

EID: 84875968406     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit044     Document Type: Note

References (16)

1. Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207:1359-69.
2. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIVpositive patients. AIDS 2010; 24:1667-78.
3. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70. (Pubitemid 29135798)
4. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-83. (Pubitemid 43855050)
5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
6. Inker LA, Wyatt C, Creamer R, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61:302-9.
7. Lowry F. CKD-EPI trumps MDRD study equation in broad range of populations. Nephrology Times 2012; 5:8-9.
8. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20-9.
9. Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 2009; 111: c39-48.
10. Wasser WG, Tzur S, Wolday D, et al. Population genetics of chronic kidney disease: the evolving story of APOL1. J Nephrol 2012; 25:603-18.
11. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-75.
12. Calza L, Trapani F, Salvadori C, et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scand J Infect Dis 2013; 45:147-54.
13. Reyataz (atazanavir sulfate) [package insert]. Princeton, NJ: Bristol-Myers Squibb, March 2012 (revised). http://packageinserts.bms. com/pi/pi-reyataz.pdf. Accessed 19 January 2013.
14. Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215-8. (Pubitemid 46763296)
15. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIVinfected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262-9.
16. Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004; 18:705-6. (Pubitemid 38393477)